We thank Michèl Willemsen and colleagues for their interest in the ATTeST trial of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia.1 The two doses studied in ...

William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University ... of data from its prior Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem ...

(Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment ... data from patients with Ataxia-Telangiectasia (A-T) treated ...

including for the potential treatment of Ataxia-Telangiectasia (A-T), Duchenne muscular dystrophy (DMD), and other potential indications, related development and commercial-stage inflection point ...

SOUTH SAN FRANCISCO, Calif. - Quince Therapeutics, Inc. (NASDAQ: QNCX), a biotech firm focusing on rare diseases with a current market capitalization of $67.76 million, has received a Notice of ...

(Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the online publication of safety data from ...

Ataxia-Telangiectasia (A-T), today, Friday, February 7, 2025, beginning at 10:00 a.m. Eastern Time. The webinar will feature leading A-T KOL Mary Kay Koenig, M.D., who will: 1) provide an A-T natural ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

The treatment was generally well-tolerated, with most adverse events being mild to moderate. This recent data supports further evaluation of EryDex for Ataxia-Telangiectasia treatment. These ...